Showing results (41-50 of 120) with videos related to

Sort By:
Pageof 12
Neoplasia (New York, N.Y.)|September 24, 2016
Induction of Activating Transcription Factor 3 Is Associated with Cisplatin Responsiveness in Non-Small Cell Lung Carcinoma CellsJair Bar, Mohamed S Hasim, Tabassom Baghai, et al.
Journal of Oncology|September 23, 2020
Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLCOmer Gal, Elizabeth Dudnik, Ofer Rotem, et al.
Clinical Lung Cancer|December 28, 2013
Genetic mutation screen in early non--small-cell lung cancer (NSCLC) specimensJair Bar, Maya Damianovich, Goni Hout Siloni, et al.
Journal of Breath Research|June 9, 2016
Cancerous glucose metabolism in lung cancer-evidence from exhaled breath analysisTali Feinberg, Layah Alkoby-Meshulam, Jens Herbig, et al.
The Israel Medical Association Journal : IMAJ|December 31, 2020
Rising Incidence of Lung Cancer in Arab Females, Jewish Females, and Arab Males from 1990 to 2014 in IsraelJair Bar, Marina Perelman, Damien Urban, et al.
Plos One|April 23, 2021
Mesencephalic astrocyte-derived neurotrophic factor is secreted from interferon-γ-activated tumor cells through ER calcium depletionMichael Peled, Tali H Bar-Lev, Efrosiniia Talalai, et al.
CA: a Cancer Journal for Clinicians|July 17, 2025
Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease managementMaxime Borgeaud, Timothée Olivier, Jair Bar, et al.
Molecular Medicine (Cambridge, Mass.)|July 4, 2026
PD-L1 and PD-L2 regulate in cell-autonomous and N-glycosylation-dependent manners the pro-tumorigenic characteristics and functions of human cancer-associated fibroblastsAlaa Abu Raiya, Tsipi Meshel, Iris Kamer, et al.
Frontiers in Oncology|March 29, 2021
BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase InhibitorsElizabeth Dudnik, Jair Bar, Assaf Moore, et al.
International Journal of Cancer|September 3, 2020
Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real-world evidenceElizabeth Dudnik, Mor Moskovitz, Abed Agbarya, et al.
Pageof 12